The availability of 750mcg teriparatide therapy in Australia has seen modest distribution . Currently, it’s largely prescribed for patients with severe osteoporosis that other treatments have failed . Obtaining this more potent formulation can be restricted due to specialist prescription requirements and limited hospital stock . Although some pro